SECTION I · THE BRIEF
Brief #81512Updated 19 AUG 2026WATERTOWN, MAGreenhouseMEDICAL ORGANIZATIONS
Employbl Company Profile

Director or Senior Director, CMC Program Management

Kymera Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the…

Location
Watertown, MA
Company size
253–253
Posted
6d ago
Via
Greenhouse
Section II · Premium ProfileMembers only
  • 01Comp band & equity packageLocked
  • 02Seniority & experience requirementsLocked
  • 03Interview process & rubricLocked
  • 04Hiring manager & team contextLocked
  • 05Growth trajectory in this roleLocked
  • 06Offer & decision timelineLocked

7-day free trial · $25/mo · cancel anytime

Kymera Therapeutics logo

Director or Senior Director, CMC Program Management · Kymera Therapeutics

View company profile
Job title
Director or Senior Director, CMC Program Management
Job location
Watertown, MA
Job description

Who we are:

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn

 

How we work:

  • PIONEER: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
  • COLLABORATE: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
  • BELONG: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.

 

How you’ll make an impact:

  • Drive end-to-end CMC program management for mid to late-stage programs, including timeline development, critical path identification, risk assessment, and execution tracking.
  • Build and maintain integrated plans spanning drug substance, drug product, analytical, quality, regulatory, and supply chain workstreams.
  • Support planning and execution of Phase 3, registration and validation campaigns, commercial-scale technology transfer, and commercial readiness activities for oral solid dosage forms.
  • Conduct CMC team meetings; ensure clear, timely communication of status, risks, decisions, and issues
  • Participate in CDMO/CRO meetings to monitor status, action items, and risks, and ensure alignment with CMC plans. Proactively identify items that require action.
  • Coordinate preparation, review, and on-time delivery of CMC components for global regulatory filings, in partnership with Regulatory Affairs and subject matter experts.
  • Serve as the CMC timeline and deliverables go-to contact for CMC function leads, core team program managers, and cross-functional partners.
  • Develop CMC best practices for decision-making and scenario planning.
  • Promote a culture of cross-functional collaboration and execution excellence.

 

Skills and experience you’ll bring:

  • PhD., M.S., or equivalent in pharmaceutics, pharmaceutical sciences, chemistry, chemical engineering, or a related discipline, with 10+ years (Ph.D.) or 15+ years (M.S.) of CMC experience; Sr. Director level requires commensurate additional experience and demonstrated scope.
  • CMC program/project management experience for oral small molecule programs, with experience advancing programs through Phase 3, NDA/MAA submission, process validation, and approval.
  • Broad CMC technical knowledge spanning drug substance, drug product, and analytical development, with sufficient depth to challenge assumptions, assess risk, and support troubleshooting.
  • Prior experience in working with CDMOs and CROs, technology transfer, GMP manufacturing, and commercial supply management.
  • Working knowledge/experience in global CMC regulatory requirements and expectations (FDA, EMA, ICH), GMP/GLP compliance, and inspection readiness.
  • Proven ability to manage complex, cross-functional programs and translate technical concepts into executable plans.
  • Exceptional communication, organizational skills and attention to detail.
  • Proficiency with project management tools (e.g., MS Project, Smartsheet, or equivalent) for integrated timeline and resource planning.

                                                                                                                                                                                

 

 

Equal Employment Opportunity

Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.

 

Compensation

  • Kymera offers a competitive compensation package that recognizes both results and capabilities through market-based, performance-driven pay.
  • The anticipated base salary range for this role is $195,000 – $330,000, with eligibility for annual bonus, equity participation, and comprehensive benefits.
  • Actual salary is based on a holistic evaluation of the specific role/level as well as each candidate’s depth of experience and the capabilities they bring to the position.

 

 

View job listing ↗
The Saturday Briefing

Get the Saturday tech briefing

New company profiles, funding moves, and who’s hiring across the market — every Saturday morning.

Where this role is based

Watertown, MA

Loading map…

Kymera Therapeutics headquarters

Watertown, MA

Company size

253253 employees

Founded

2017

Total raised

$1,956,800,000

View company profile ↗

Funding rounds

  • Post Ipo Equity$602M
  • Post Ipo Equity$250.8M
  • Post Ipo Equity$225M
  • Post Ipo Equity$275M
  • Post Ipo Equity$150M
  • Post Ipo Equity$257M
  • Series C$102M
  • IPOUndisclosed
  • Series B$65M
  • Series A$30M